Description: SD-169 (SD 169) is a selective and ATP competitive the MAP kinases p38alpha and p38beta inhibitor. Target: p38 MAPK. Smiles: NC(=O)c1ccc2[nH]ccc2c1. References: Myers R R , Sekiguchi Y , Kikuchi S , et al. Inhibition of p38 MAP kinase activity enhances axonal regeneration[J]. Experimental Neurology,...

SD 169 is a selective ATP competitive inhibitor of the MAP kinases p38alpha (IC50 = 3.2 nM) and p38beta (IC50 = 122 nM). It has no inhibitory effect against a panel of other kinases, including p38gamma MAP kinase, ERK2, JNK-1, and MAPKAPK-2, when tested in vitro at 50 µM. SD 169 is orally active, significantly...

Soluble in DMSO or ethanol. SD169 is an orally available, ATP-competitive, isoenzyme-selective Mitogen-Activated Protein Kinase (MAPK) inhibitor. It is 38 times more potent against p38alpha MAP kinase (IC(50) of 3.2nM) over p38beta MAP kinase (IC(50) of 122nM). Target: MAPK - p38 , Kinase Group: CMGC , Substrate:...